Mania News and Research

RSS

Factors linked to relapse risk in bipolar disorder identified

A higher number of previous mood episodes and living in a mixed urban/rural area are associated with an increased risk for relapse in patients with bipolar disorder, Spanish researchers report.

1 Jun 2012

Ketamine reduces suicidal thoughts in patients with bipolar depression

Bipolar disorder is a serious and debilitating condition where individuals experience severe swings in mood between mania and depression. The episodes of low or elevated mood can last days or months, and the risk of suicide is high. Antidepressants are commonly prescribed to treat or prevent the depressive episodes, but they are not universally effective. Many patients still continue to experience periods of depression even while being treated, and many patients must try several different types of antidepressants before finding one that works for them.

31 May 2012

Anxiety increases symptom severity in acute mania patients

Anxiety is common in patients experiencing an episode of acute mania and is associated with more severe mood symptoms, researchers report.

30 May 2012

Study shows effects of psychotropic drug treatment on brain morphology

It is increasingly recognized that chronic psychotropic drug treatment may lead to structural remodeling of the brain. Indeed, clinical studies in humans present an intriguing picture: antipsychotics, used for the treatment of schizophrenia and psychosis, may contribute to cortical gray matter loss in patients, whereas lithium, used for the treatment of bipolar disorder and mania, may preserve gray matter in patients.

9 May 2012

Johnson & Johnson fined $1.2B for hiding anti-psychotic drug dangers, deceptive marketing

An Arkansas judge fined the drug maker and a subsidiary for misleading doctors and the public on the risks involved with taking an anti-psychotic drug, Risperdal, and for marketing the drug for an off-label use to the state's Medicaid system.

12 Apr 2012

Scientists gain insight into why lithium salts are effective at treating bipolar disorder

Scientists have gained insight into why lithium salts are effective at treating bipolar disorder in what could lead to more targeted therapies with fewer side-effects.

14 Mar 2012

Viewpoints: America's mixed views on health; Contraception and political 'excesses'; Colorado Medicaid debate

Most people tell pollsters they like the parts of the law that have gone into effect: health insurance for people with preexisting conditions, a clause that allows children to stay on their parents' health plans until the age of 26 and discounts for prescription drugs on Medicare. And, as time goes by, Americans seem less worried that the law will have a negative effect on their own medical care ... But the law itself isn't any more popular than the day it passed.

12 Mar 2012

Gedeon Richter and Forest Labs' cariprazine Phase III trials on schizophrenia meet primary endpoint

Forest Laboratories, Inc. and Gedeon Richter Plc. today announced positive top-line results in 2 Phase III clinical trials of cariprazine (RGH-188) for the treatment of acute exacerbation of schizophrenia.

28 Feb 2012

DBS safe and effective for treatment-resistant depression in patients with unipolar MDD or BP

A new study shows that deep brain stimulation (DBS) is a safe and effective intervention for treatment-resistant depression in patients with either unipolar major depressive disorder (MDD) or bipolar ll disorder.

3 Jan 2012

Current scientific understanding of left and right-handedness

Left-handedness is sometimes the expression of a genetic defect or an early developmental disturbance. In this issue of Deutsches Ärzteblatt International, Stefan Gutwinski and coauthors present the current scientific understanding of left- and right-handedness.

28 Dec 2011

Articles explore clinical dilemma about children's behavioral problems

Clinicians often face the challenge of trying to make sense of conflicting reports from parents, teachers, and children about a child's behavioral problems. However, a better understanding of the source and nature of these disagreements may provide important information that could improve treatment and outcomes. A group of articles in the current issue of Journal of Child and Adolescent Psychopharmacology, a peer-reviewed journal published by Mary Ann Liebert, Inc., explores this challenging clinical dilemma.

2 Nov 2011

Forest Laboratories second quarter net sales increase 9.0% to $1,130.3 million

Forest Laboratories, Inc., an international pharmaceutical manufacturer and marketer, announced that reported earnings per share equaled $0.91 in the second quarter of fiscal 2012. Reported earnings per share in the second quarter of fiscal 2011 were $1.00.

18 Oct 2011

Common DNA variations contribute to schizophrenia, bipolar disorder

A team of over 250 researchers from more than 20 countries have discovered that common genetic variations contribute to a person's risk of schizophrenia and bipolar disorder.

20 Sep 2011

ERWW PR forms Health Buzz Group

Euro RSCG Worldwide PR (ERWW PR) announces the formation of its Health Buzz Group, a global division created in response to growing client interest in big, splashy “wows” from small budgets in quick time frames using traditional and social media to generate momentum.

20 Sep 2011

Scientists discover common genetic variants associated with schizophrenia and bipolar disorder

Common genetic variants contribute to the risk of schizophrenia and bipolar disorder, an international research consortium has discovered.

19 Sep 2011

Landmark international study confirms common genetic contribution to mental illness

An international research consortium has confirmed that common genetic variants contribute to a person’s risk of schizophrenia and bipolar disorder. The largest study of its kind provides new molecular evidence that 11 regions have strong association with these diseases, including six regions not previously observed. The researchers also found that many of these DNA variations contribute to both diseases. The findings, reported by the Psychiatric Genome-Wide Association Study Consortium (PGC) and published online in two papers in the journal Nature Genetics, represent significant advances in the understanding the causes of these severe and often debilitating disorders.

18 Sep 2011

Risperidone recall by J&J

Ortho-McNeil-Janssen Pharmaceuticals Inc., a unit of Johnson & Johnson, recalled about 16,000 bottles of its Risperdal schizophrenia drug on reports of an uncharacteristic odor. The recall affects one lot that was shipped between Aug. 27, 2010, and Feb. 15, 2011.

19 Jun 2011

Homelessness and mental illness link explored in RMIT study

In a new study by the RMIT University, Victoria researchers looked at cases of 4,291 people using homelessness services in the city. Dr Guy Johnson and Professor Chris Chamberlain found almost half of them - 46 per cent - lost their homes after a family breakdown. This is contrary to the long held belief that most homeless people are mentally unstable.

7 Jun 2011

Psychotherapeutic treatment can cure cyclothymic disorder

In the current issue of Psychotherapy and Psychosomatics a group of Italian investigators headed by Giovanni Fava published a randomized controlled trial on psychotherapeutic treatment of cyclothymic disorder, a disturbance that is characterized by rapid alternation of mood swings.

9 May 2011

Catherine Zeta Jones treated for bipolar disorder

Catherine Zeta Jones – the 41-year-old Welsh actor checked into a day clinic in Connecticut for five days earlier this month for the treatment of bipolar disorder. “After dealing with the stress of the past year, Catherine made the decision to check in to a mental health facility for a brief stay to treat her Bipolar II Disorder,” said publicist Cece Yorke said in a statement adding, “She's feeling great and looking forward to starting work this week on her two upcoming films.”

13 Apr 2011